Sexual dysfunction

Mammogen and Brilliantly Combine Forces to Advance Community Efforts for Breast Cancer Previvors and Survivors

Thursday, October 14, 2021 - 6:35pm

Brilliantly and Mammogen, Inc., two female-led womens health companies centered around breakthrough technologies designed to solve unmet clinical needs associated with breast cancer, announce a comprehensive partnership expected to improve quality of care for the breast cancer community, both inside and outside of the physicians office.

Key Points: 
  • Brilliantly and Mammogen, Inc., two female-led womens health companies centered around breakthrough technologies designed to solve unmet clinical needs associated with breast cancer, announce a comprehensive partnership expected to improve quality of care for the breast cancer community, both inside and outside of the physicians office.
  • The companys flagship genTRU-breastTM program leverages novel messenger RNA (mRNA) technology to non-invasively detect and diagnose breast cancer.
  • Brilliantly helps women with the transition from confronting breast cancer to embracing life through innovative products, thoughtful content, and relevant services.
  • The company has recently released their flagship technology, Brilliantly Warm, the first-ever wearable designed specifically for women who have had breast reconstruction surgery.

NAFC names Renovia, developer of the leva® Pelvic Health System, as Trusted Partner

Tuesday, October 12, 2021 - 2:00pm

"NAFC has long been an advocate for improving pelvic health," said Steve Gregg, executive director of the non-profit NAFC.

Key Points: 
  • "NAFC has long been an advocate for improving pelvic health," said Steve Gregg, executive director of the non-profit NAFC.
  • PFD Week offers an additional and much-needed reminder of how important pelvic floor health is to preventing incontinence.
  • The leva Pelvic Health System offers a novel, non-invasive, medication-free way for women to train and strengthen their pelvic floor musclesat home in just five minutes a dayto treat urinary incontinence (UI).
  • For more information about Renovia or the leva Pelvic Health System please visit www.renoviainc.com or follow the company on Twitter , Facebook , LinkedIn and Instagram .

Love Pharma Makes Public Debut in Emerging Sexual Health, Wellness, and Psychedelics Markets

Monday, October 4, 2021 - 1:45pm

One market advantage that Love Pharma will enjoy over many of its competitors during its development process is the companys demand for clinical validation.

Key Points: 
  • One market advantage that Love Pharma will enjoy over many of its competitors during its development process is the companys demand for clinical validation.
  • Psychedelics, like psilocybin, may be an emerging market, but according to a report from Research and Markets, its an exploding market.
  • Sexual health and wellness can encompass a wide range of products from sexual enhancement to sexual dysfunction to lubricants.
  • To learn more about Love Pharma Inc., visit https://love-pharma.com or email investors@love-pharma.com
    Love Pharma Inc. is a Canadian Securities Exchange-traded company.

Global Pelvic Floor Electric Stimulator Market Size, Share & Trends Analysis Report 2021-2028: Asia-Pacific Expected to Significantly Lead the Market from 2021 to 2028 - ResearchAndMarkets.com

Monday, October 4, 2021 - 12:40pm

The "Global Pelvic Floor Electric Stimulator Market Size, Share & Trends Analysis Report by Application (Urinary Incontinence, Neurodegenerative Diseases, Sexual Dysfunction), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pelvic Floor Electric Stimulator Market Size, Share & Trends Analysis Report by Application (Urinary Incontinence, Neurodegenerative Diseases, Sexual Dysfunction), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global pelvic floor electric stimulator market size is anticipated to reach USD 427.15 million by 2028.
  • It is expected to expand at a CAGR of 11.5% from 2021 to 2028.
  • The increasing prevalence of chronic diseases and Urinary Incontinence (UI) are primary factors that are expected to drive the market growth.

Wouche Away™ Prebiotic Total Body Cleanser by Glyciome, LLC Chosen as Finalist for 2021 Idaho Innovation Award's Consumer Product of the Year

Thursday, September 30, 2021 - 5:30pm

Wouche Away is the first consumer product by Glyciome (a women-owned LLC).

Key Points: 
  • Wouche Away is the first consumer product by Glyciome (a women-owned LLC).
  • It was developed, and is manufactured, in Glyciome facilities at the University of Idaho Research Park (Post Falls, Idaho).
  • "We are ecstatic to be chosen as a finalist for the 2021 Idaho Consumer Product of the Year," said Glyciome Chief Executive Officer and Wouche Away co-inventor Dr. Joanna Ellington (glyciome.com).
  • Wouche Away can be purchased online at woucheaway.com or Amazon, and in regional Spokane and Coeur d'Alene retail locations.

MysteryVibe Research Finds Sexual Wellness Products For Older Adults Need Different Design

Tuesday, September 21, 2021 - 9:53am

LOS ANGELES, Sept. 21, 2021 /PRNewswire/ -- Declining health amongst older people is often linked to increased sexual dysfunction with age. Yet few products are designed to cater to this demographic. MysteryVibe's new research tackles this head-on and identifies the key factors that will lead to better, more accessible and useful products for older people.

Key Points: 
  • Sexual wellness products should be tools that give older people control and confidence in their sexual health experiences.
  • Sexual wellness brand, MysteryVibe , recently ran a research study with healthcare professionals and product designers to identify the top considerations when making products that can help with life's evolving stages of intimacy.
  • Most sexual wellness products on the market are designed for healthy, able-bodied young adults.
  • MysteryVibe is bridging the gap of accessibility in sexual wellness products by sharing its expertise in product specifications for older people.

MysteryVibe Research Finds Sexual Wellness Products For Older Adults Need Different Design

Tuesday, September 21, 2021 - 9:49am

Sexual wellness products should be tools that give older people control and confidence in their sexual health experiences.

Key Points: 
  • Sexual wellness products should be tools that give older people control and confidence in their sexual health experiences.
  • Sexual wellness brand, MysteryVibe , recently ran a research study with healthcare professionals and product designers to identify the top considerations when making products that can help with life's evolving stages of intimacy.
  • Most sexual wellness products on the market are designed for healthy, able-bodied young adults.
  • MysteryVibe is bridging the gap of accessibility in sexual wellness products by sharing its expertise in product specifications for older people.

Renovia's leva® Pelvic Health System is First Femtech Offering Included in Product Library of Digital Therapeutics Alliance

Friday, September 17, 2021 - 5:57pm

Renovia is the first company focused solely on women's health to have a product included in the DTA Product Library.

Key Points: 
  • Renovia is the first company focused solely on women's health to have a product included in the DTA Product Library.
  • Alliance members align with its mission to improve clinical and health economic outcomes using high quality, evidence-based digital therapeutics to prevent, manage, or treat a medical disorder or disease.
  • "Women's health is a critical segment of the overall digital therapeutics ecosystem, so we're thrilled to see leva added as the first 'femtech' offering in our Product Library.
  • Inclusion in DTA's Product Library is further affirmation of Renovia's evidence-based approach to pelvic health that promises to extend the reach of clinical care and improve health equity.

Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

Thursday, September 9, 2021 - 12:30pm

TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD).

Key Points: 
  • TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD).
  • Through Field Trip Discovery, its drug development division, Field Trip is developing next-generation psychedelic molecules.
  • Major depressive disorder (MDD), treatment-resistant depression (TRD) and postpartum depression (PPD) share similar etiologies and negatively impact functioning.
  • About Field Trip Health Ltd.
    Field Trip is a global leader in the development and delivery of psychedelic therapies.

The IMA Group Continues Growth with Acquisition of Albuquerque Neuroscience, Inc.

Thursday, September 9, 2021 - 12:02pm

The IMA Group (IMA) announced today the acquisition of Albuquerque Neuroscience, Inc., a clinical research site specializing in diseases of the central nervous system (CNS) and general medical conditions.

Key Points: 
  • The IMA Group (IMA) announced today the acquisition of Albuquerque Neuroscience, Inc., a clinical research site specializing in diseases of the central nervous system (CNS) and general medical conditions.
  • Albuquerque Neuroscience joins IMAs Clinical Research Division , which specializes in Phase II-IV clinical trials in all therapeutic areas.
  • The acquisition adds another high-quality clinical trial site to IMA Clinical Research while further expanding its national footprint.
  • IMA Clinical Research, a division of The IMA Group, is a physician-founded network of integrated clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas.